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Abstract 
Scope; Inadequate maternal folate intake is associated with increased childhood acute 
lymphoblastic leukaemia (ALL) risk. Folate provides methyl groups for DNA methylation, 
which is dramatically disrupted in ALL. We investigated if maternal folate (and related B-
vitamin) intake during pregnancy may affect ALL risk via influencing DNA methylation. 
Methods and Results; We identified genes in which methylation changes were reported 
both in response to folate status and in ALL. Folate-responsive genes (n=526) were 
identified from mouse models of maternal folate depletion during pregnancy. Using 
published data, we identified 2621 genes with persistently altered methylation in ALL. 
Twenty-five overlapping genes were found, with the same directional methylation change in 
response to folate depletion and in ALL. We confirmed hypermethylation of a subset of 
genes (ASCL2, KCNA1, SH3GL3, SRD5A2) in ALL by measuring 20 patient samples using 
pyrosequencing. In a nested cohort of cord blood samples (n=148), SH3GL3 methylation was 
inversely related to maternal RBC folate concentrations (p=0.008).  Furthermore, ASCL2 
methylation was inversely related to infant vitamin B12 levels. (p=0.016). Conclusion; 
Findings demonstrate proof of concept for a plausible mechanism i.e. variation in DNA 
methylation, by which low intake of folate, and related B-vitamins during pregnancy may 
influence ALL risk.  
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Introduction 
Increasingly, evidence from epidemiological studies suggests that maternal folate intake 
prior to and during pregnancy may influence the risk of the development of childhood acute 
lymphoblastic leukaemia (ALL)[1-7].  The first study to report a protective association 
between maternal folate and ALL risk observed an odds ratio (OR) of 0.40 (Confidence 
Intervals (CI) 0.21-0.73) for self-reported folate supplementation taken at any time, for any 
duration, during pregnancy[7].  Although this initial study was fairly small (83 cases and 166 
controls), subsequent larger studies have also reported significant inverse associations 
between self-reported folate supplementation before or during pregnancy and ALL risk (OR 
= 0.4 (CI 0.3-0.6)[2] and 0.80 (0.71-0.89)[5]). Further studies found associations between 
higher folate intake, assessed by retrospective food frequency questionnaires, at specific 
times during pregnancy and altered ALL risk.  Whilst Bailey et al observed that higher dietary 
folate intake during the last 6 months of pregnancy was protective[3], Singer et al reported 
that higher maternal intake of one-carbon metabolism nutrients and supplements 
combined in the year before pregnancy reduced offspring ALL risk[6]. Similarly, Ajrouche et al 
found that self-reported folate supplementation implemented 3 months preceding, but not 
during, pregnancy may reduce childhood leukaemia risk (OR 0.7 (0.5-1.0))[1]. This finding was 
supported by the largest meta-analysis to date, which observed that folate supplementation 
pre-conception reduces ALL risk (OR: 0.69, 95%CI: 0.50-0.95)[4]. Furthermore, genetic studies 
investigating the influence of both parental and offspring variants of folate metabolising 
genes on childhood ALL risk corroborate the hypothesis that lower folate status may 
enhance disease risk [2, 8-12]. The observational evidence that in utero folate exposure may 
modulate risk of childhood ALL development is consistent but, to date, there is limited 
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insight into the underlying mechanism through which folate status prior to, and during, 
pregnancy may be involved in disease development. 
Childhood ALL arises from initial genetic abnormalities such as chromosomal rearrangement 
and hyperdiploidy.  These abnormalities may occur in utero [13-17], and remain latent until a 
‘secondary hit’ leads to overt disease. Indeed, the ETV6-RUNX1 fusion, which occurs in 
approximately 25% of B-cell precursor ALL cases[18], was present in 1% of the population at 
birth; this is a 100-fold higher prevalence than for this disease subtype [16] suggesting that, 
whilst key in the disease pathway, the presence of this translocation alone is not sufficient 
to cause disease. 
DNA methylation is an important mechanism of gene regulation and methylation of CpG 
rich regions may inhibit binding of the regulatory machinery and lead to gene silencing[19].  
As with all cancers, altered DNA methylation patterns have been widely documented in ALL 
[20-26].  It is therefore plausible that gene dysregulation arising from aberrant DNA 
methylation may contribute to the aetiology of childhood ALL, and thus be a potential 
‘second hit’ mechanism in the causal disease pathway. Furthermore, whilst the DNA 
sequence is generally resistant to change in response to non-carcinogenic environmental 
factors, DNA methylation is more plastic and is altered by a variety of environmental and 
lifestyle exposures [27]. Since folate is a key source of methyl groups for synthesis of S-
adenosyl methionine (SAM) – the universal methyl donor – it is an attractive candidate 
nutrient for the modulation of DNA methylation.  Altered intakes of folate during pregnancy 
can have profound effects on DNA methylation patterns in the offspring, as has been 
reported in both animal models[28-33] and human studies[34, 35].  It is therefore plausible that 
altered DNA methylation may be an underlying mechanism through which maternal folate 
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intake prior to, and during, pregnancy may modulate risk of childhood ALL.  Moreover, 
through their effects on the synthesis of SAM, related micronutrients driving one carbon 
metabolism, i.e. vitamins B2, B6 and B12, may also modulate DNA methylation patterns and, 
hence, ALL risk.  Indeed, higher maternal dietary B12 intake has been associated with 
decreased offspring ALL risk[3], and vitamin B12 has also been reported to influence DNA 
methylation patterns [36-39].  
We therefore hypothesised that reduced intake of folate (and other B vitamins) during 
pregnancy may alter DNA methylation in genes that are also aberrantly methylated in 
childhood ALL.  To investigate this hypothesis, we used a ‘meet in the middle’ approach [40] 
to identify genes that have altered DNA methylation in response to maternal folate 
depletion and are also aberrantly methylated in childhood ALL (see Figure 1).  We utilised 
data from our mouse model of maternal folate depletion [29, 33] to determine genes which 
have altered methylation in response to maternal folate depletion. We then compared this 
list of genes with a compiled list of genes from the literature that have been reported to 
have altered DNA methylation in ALL. We confirmed aberrant DNA methylation in a panel of 
target genes in ALL patient samples, and investigated the association of maternal and infant 
folate and vitamin B12 status on methylation of those loci in a population of healthy infants 
at birth.        
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Materials and Methods 
Identification of genes with altered DNA methylation in relation to maternal folate depletion 
AND in childhood ALL  
We previously reported altered DNA methylation in response to maternal folate depletion in 
fetal and adult mouse models [29, 33].  Briefly, female C57Bl/6 mice were randomised to low 
or normal folate diets (0.4 or 2mg folic acid/kg diet) 4 weeks prior to mating.  Mice were 
maintained on these diets throughout pregnancy, and throughout weaning (4 weeks) in the 
case of the adult offspring model.  For the fetal model, dams were culled at 17.5 days’ 
gestation, and foetuses removed. For the adult model of folate depletion during pregnancy, 
offspring were weaned on to diets containing normal levels of folate (i.e. 2mg/kg) and were 
maintained on this diet until 6 months of age.  Low folate diets resulted in significantly 
lower folate status of dams compared to control fed dams (previously published data[41, 42]). 
Fetal (n=6/group) and adult (n=12/group) livers were excised from male mice, and DNA 
extracted. Promoter methylation was measured by microarray analysis following 
methylated DNA immunoprecipatation. Resultant data were assessed for quality, 
normalised and processed as described previously [29, 33]. Using data from these studies we 
compiled a list of ‘folate-responsive’ genes - i.e. those with altered DNA methylation in 
response to maternal folate intake in either fetal or adult offspring (n=526 genes) (See 
Supplementary Material).  
A list of genes reported to have altered DNA methylation in childhood ALL was determined 
using publically-available data.  A literature search was carried out in PubMed using the 
search terms ‘DNA methylation’ and ‘childhood acute lymphoblastic leukaemia’.  The 
criteria for study selection were a) methylation had been assessed at the genome-wide level 
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b) methylation was compared in ALL cases vs control samples c) methylation outcome data 
were available from the manuscript. Five studies were included for which genome-wide 
methylation had been assessed in childhood ALL cases compared with controls [20, 21, 23-25] 
(See Supplementary Material for details) and a list of 2621 gene IDs was compiled including 
those genes for which altered methylation was reported in at least 2 of the selected studies 
(See Supplementary Material).  
Folate-responsive and ALL-associated gene lists were then compared using an online list 
comparison tool (http://jura.wi.mit.edu/bioc/tools/compare.php) with gene symbols as the 
common identifiers, and excluding case sensitivity.   
Study population (and control samples) and ALL patient samples  
DNA methylation was measured at selected loci (ASCL2, KCNA1, SH3GL3, SRD5A2) in 20 DNA 
samples taken at diagnosis from either peripheral blood (n=3) or bone marrow (n=17) of ALL 
patients treated on the ALL97 trial [18]. Mean age of the patients was 1.15 years. Loci were 
selected based on having been reported in the literature to be aberrantly methylated in ALL 
and having had altered DNA methylation in response to modulated maternal folate intake in 
mice (as above).  The purpose of these measurements was to confirm that our assay 
detected expected (ALL-associated) changes in DNA methylation and hence was appropriate 
for use to measure DNA methylation at these same loci in samples for which data on human 
exposure to folate and other B vitamins in utero were available. These cases included 
KMT2A (MLL) rearrangements (n=2), high hyperdiploidy (n=7) and B-other subgroups 
(n=11). Participating centres obtained approval from the local ethics committee and written 
informed consent from patients or parents [18]. 
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The samples for which data on folate exposure were available was a nested cohort study 
population drawn from the North Cumbria Community Genetics Project [43], which included 
148 cord blood DNA samples (mean (± SD) gestation = 39.6 (1.3) weeks) in which gene 
specific DNA methylation was measured. This prospective, unselected, population-based 
cohort was collected between 1996 and 2003 at a single maternity unit in West Cumbria, 
UK. Mothers were recruited at their first antenatal appointment (mean (SD) gestation = 10.8 
(4.7) weeks) where they completed a health and lifestyle questionnaire and provided blood 
samples. Cord blood from the infant and delivery details were collected at birth. Maternal 
and infant (cord) red blood cell (RBC) folate and serum vitamin B12 analyses were conducted 
on an aliquot of whole blood removed and stabilised prior to DNA extraction at the time of 
sampling - i.e. 1st trimester for maternal sample and at birth for cord blood samples. These 
samples were also used as the control population for comparison with DNA methylation 
patterns in ALL samples.  Summary statistics are provided in the supplementary material. 
Ethical approval to undertake this study was obtained from the Newcastle and North 
Tyneside Local Research Ethics Committee (07/Q0906/5). Written informed consent was 
obtained from all participating mothers recruited during pregnancy. Consent was obtained 
for use of biological samples (including DNA) from each mother-child dyad for 
epidemiological studies. 
 
Bisulfite Pyrosequencing® for loci-specific DNA methylation analysis 
Bisulfite conversion of DNA was performed using the EZ DNA Methylation Gold™ kit (Zymo 
Research) following the manufacturer’s protocol.  Briefly, 500ng of genomic DNA was 
incubated with CT conversion reagent and incubated at the following temperatures; 98°C 
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for 10 min, 64°C for 2.5hr, held at 4°C.  DNA was then transferred to a spin column, washed, 
desulphonated and purified, finally eluting in a 10µl volume. 
Quantitative bisulfite Pyrosequencing® was used to determine the percentage methylation 
at individual CpG sites within the promoter regions of the selected genes (number of CpGs: 
ASCL2 n=7, KCNA1 n=5, SH3GL3 n=9, SRD5A2 n=5).  Briefly, 20ng of bisulfite treated DNA 
was added as a template in PCR reaction using 10µl Hot Star Taq mastermix and 1 µl of each 
forward and reverse primer (Qiagen) in a total volume 20µl.  All primer sequences and 
annealing temperatures for each assay are given in the Supplementary material. 
Amplification was carried out in a Veriti® 96-Well fast thermocycler (Life Technologies) using 
the following protocol; 95ᵒC 15 min, then 50 cycles of 95ᵒC for 15 seconds, assay-specific 
annealing temperature for 30 seconds, 72ᵒC for 15 seconds, followed by 72ᵒC for 5 min, and 
a final holding step at 4ᵒC. Biotin-labelled PCR products were captured with streptavidin 
sepharose beads (GE Healthcare), and made single stranded using sodium hydroxide 
denaturation with the aid of a Pyrosequencing® Vacuum Prep Tool (Qiagen).  Sequencing 
primers were annealed to the single stranded PCR product by heating to 80°C, followed by 
slow cooling.  Pyrosequencing® was then carried out on a Pyromark MD system.  Cytosine 
methylation was quantified using proprietary PyroQ CpG 1.0.6 software.  All PCR and 
Pyrosequencing® reactions were carried out in duplicate. 
For each assay, 0% and 100% methylated controls (Epitect, Qiagen) were routinely run 
alongside sample amplification as internal controls.  Assays were validated to rule out any 
amplification bias of primers and to assess assay reproducibility using methods described 
previously [44].   All primer sets were found to be unbiased and assays were reproducible.   
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Statistical Analysis 
To determine the distribution, one sample Kolmogorov Smirov tests were applied to CpG 
specific and mean methylation data, with all data sets shown to be normally distributed. 
Pearson’s correlation was used to assess correlation between percentage methylation at 
individual CpGs and mean percentage methylation across all CpGs for each gene. Significant 
correlations were observed for each individual CpG with mean methylation for all genes 
investigated (Supplementary Materials). To reduce false positive associations through 
multiple testing, initially mean methylation for each gene was examined in relation to the 
exposure variables maternal RBC folate, infant RBC folate, maternal vitamin B12 and infant 
vitamin B12 using linear regression.  Estimated power to detect a co-efficient>0.2 with a 
sample size of 148 is 68% at p=0.05. For those genes where associations between exposure 
variables and mean methylation were found to be statistically significant (i.e. p-value<0.05), 
each individual CpG in the given gene was analysed in relation to the specific exposure 
variable of interest using linear regression. Comparisons of mean percentage methylation 
between ‘healthy’ infants and ALL patients were analysed by univariate ANOVA. Estimated 
power to detect a 10% methylation change assuming a conservative standard deviation 
estimate of 9 in each group with an n=20 is 94% at p=0.05.  All statistical analyses were 
performed using SPSS Version 19 software (IBM Statistical Package for the Social Sciences) 
and a p-value of <0.05 was considered statistically significant.  
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Results 
Comparison of folate and ALL-associated methylation signatures 
Of the 2621 genes reported to have altered DNA methylation in ALL in at least 2 studies, 793 
did not have corresponding identifiers on the mouse array used to assess methylation 
changes in response to maternal folate depletion, and thus could not be directly compared.  
The remaining potentially comparable 1828 ALL-associated genes were compared with the 
526 genes observed to have altered methylation associated with maternal folate depletion, 
with 66 genes found to overlap (Table 1). Of these 66 genes, 34 were reported with a 
consistent direction of methylation change in ALL across at least two studies (i.e. 31 
hypermethylated; 3 hypomethylated), and therefore considered for further analysis.  
Twenty-five of the 34 genes (73.6%) that were reported to have a consistent direction of 
methylation change in ALL across studies displayed the same direction of methylation 
change in response to maternal folate depletion - i.e. hypermethylation. Of the 34 genes 
with consistent methylation change across studies, 4 were selected at random for DNA 
methylation quantification of the promoter region by pyrosequencing analysis (ASCL2, 
KCNA1, SH3GL3 and SRD5A2). Methylation was assessed in ALL cases to confirm 
methylation at the region of the gene measured by these newly-designed pyrosequencing 
assays was detectably higher in ALL disease samples compared with a healthy population 
(i.e. cord blood samples).  Whilst use of the cord blood samples as a comparator has 
limitations due to lack of age and sample type matching, it is appropriate in this instance to 
merely confirm the utility of the assays to capture ALL-associated hypermethylation 
previously reported elsewhere. As expected, mean methylation of all selected genes were 
statistically significantly higher in blood/bone marrow samples from ALL patients when 
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compared with infant cord blood samples (Figure 2). We then subsequently tested for 
associations between DNA methylation and measures of folate and vitamin B12 exposures.  
 
Association between maternal RBC folate and vitamin B12 on infant gene methylation at 
birth 
A statistically significant inverse relationship was observed between mean DNA methylation 
of the SH3GL3 gene and maternal RBC folate (p=0.008; Coefficient (95%CI) 0.218 (-0.002-
0.000)) Figure 3C).  This pattern of altered methylation was seen at multiple CpG sites across 
the region (Supplementary Material). No associations were observed between mean 
methylation at the ASCL2, KCNA1 and SRD5A2 loci and maternal RBC folate status during 
pregnancy (Figure 3A, B & D). 
Furthermore, no associations were observed between mean methylation of any of the loci 
investigated and maternal vitamin B12 status (Figure 4).  
 
Association between infant RBC folate and vitamin B12 with infant gene methylation at 
birth 
Mean methylation at the loci investigated were not significantly associated with infant RBC 
folate status at birth (Figure 5).  
A statistically significant inverse relationship was observed between mean methylation of 
the ASCL2 gene and infant vitamin B12 concentration (p=0.016; Coefficient (95%CI) 0.201 (-
0.002-0.000)) Figure 6A).  This relationship was observed for multiple CpG sites across the 
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region (Supplementary Material). Mean methylation at the KCNA1, SH3GL3 and SRD5A2 loci 
were not significantly associated with infant vitamin B12 status at birth (Figure 6B-D). 
Discussion 
We hypothesised that, since folate is a key nutrient driving one carbon metabolism towards 
the production of SAM for the methylation of biological molecules, aberrant DNA 
methylation may be an underlying mechanism for the observed inverse associations 
between maternal folate intake during pregnancy and childhood ALL risk.  To investigate this 
hypothesis we employed a ‘meet in the middle’ approach [40] to identify overlap between 
folate and ALL-associated methylation signatures to test the plausibility that folate-
associated altered methylation may be mechanistically involved in the causal pathway 
towards childhood ALL (Figure 1).  Of the genes reported to have a consistent direction of 
methylation change in ALL across studies (n=34), 73.5% also displayed the same direction of 
methylation change in response to folate depletion. Thus, in individuals harbouring ALL-
initiating genetic abnormalities, maternal folate depletion may contribute to the causal 
disease pathway through altered DNA methylation of ALL-associated genes.  
In this study we utilised previously published data from our mouse model [29, 33] to identify 
genes with methylation change associated with maternal folate depletion.  Whilst human 
studies investigating the influence of maternal folate intake on offspring methylation have 
been conducted, there is a lack of reproducibility between these studies, with no 
concordant gene loci found between data sets (reviewed in [45]).  Whilst this is plausibly due 
to differences in sample type, study population (including genetic diversity), study design, 
platform used to assess methylation and statistical analyses, confounding factors are likely 
to be major contributors to the observed differences between human studies. Since data 
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derived from experimental studies in inbred models are not subject to the same level of 
reporting bias, genetic heterogeneity and potential confounding factors as human studies 
due to more strict control of experimental parameters, this novel approach enabled us to 
include truly folate-responsive gene loci in our analysis.  In this way, data from animal 
models may be useful in informing human studies where associations between 
environmental exposures and methylation patterns may be difficult to determine due to a) 
the difficulty in measuring or assessing certain exposures b) the large numbers of 
participants required to reveal small changes in methylation in association with poorly 
defined exposure variables and c) the large number of potential confounding factors in 
human studies.   
It is pertinent to highlight, that the ALL-associated methylation signature was derived from 
studies measuring methylation in diseased cells, and therefore some of the aberrant 
methylation signature is likely to be a consequence of disease rather than causal.  
Therefore, to distinguish those methylation marks that are causal for, from those that are 
consequences of, disease, measurements prior to diagnosis would be required.  Given the 
rarity of childhood ALL and lack of available pre-diagnostic samples, currently very little is 
known about early initiating epigenetic events in the development of childhood ALL.  The 
utilization of historical collections of neonatal blood spot samples or collective cases from 
multiple large cohort studies may facilitate investigation of pre-diagnostic methylation 
patterns, but are unlikely to have associated exposure data or may be underpowered to 
detect epigenetic changes in association with exposure. Therefore, novel methodologies, 
such as the current meet in the middle approach, are required to ascertain the plausibility of 
biological mechanisms by which environment may influence childhood ALL development. 
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Further investigations using approaches such as one and two step Mendelian 
Randomisation approaches[46] will be key in providing evidence of causality.       
To seek evidence for an effect of folate exposure in utero in humans on DNA methylation of 
genes found to be hypermethylated in ALL and therefore of potential relevance to disease 
causality, we assessed methylation of a subset of target genes (ASCL2, KCNA1, SH3GL3 and 
SRD5A2) in healthy newborns in relation to maternal and infant folate status, and in ALL 
patients. Given that folate and B12 are key micronutrients driving one carbon metabolism, 
and that maternal vitamin B12 has been associated with offspring ALL risk [3], we also 
investigated the association between maternal and infant B12 status and methylation of 
these target genes.  Lower maternal folate status was significantly associated with higher 
methylation of the SH3GL3 locus.  Therefore, since low maternal folate is associated with 
increased ALL risk [1-7] and SH3GL3 hypermethylation is reported in ALL [20, 21, 24], the 
observed association between low folate and SH3GL3 hypermethylation supports our 
hypothesis that low maternal folate intake during pregnancy may increase risk of ALL via 
hypermethylation of the SH3GL3 locus.  In particular, infants born to mothers with above 
normal (600ng/ml) RBC folate levels tended to have the lowest SH3GL3 methylation, which 
may indicate that higher than normal levels of folate are protective. This theory is supported 
by evidence that folate supplementation is protective against ALL [1, 2, 4, 5, 7]. We also report a 
significant inverse association between infant vitamin B12 status and ASCL2 methylation. This 
finding is in keeping with the hypothesis that aberrant DNA methylation may be one 
potential biological mechanism facilitating the previously observed association between low 
vitamin B12 status and ALL risk i.e. low vitamin B12 status may increase ALL risk through 
hypermethylation of ASCL2 and, possibly, other genes [3].      
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Whilst the associations observed between SH3GL3 and ASCL2 methylation and maternal 
folate and infant B12 status respectively are statistically significant, the range of methylation 
differences that we report are fairly small.  Whilst these relatively small changes in 
methylation in response to environmental factors are a common finding in epidemiological 
studies [34, 47], the functional consequences of such small effects have often been 
questioned.  It is important to bear in mind that, whilst DNA methylation is often reported 
as a percentage (i.e. reports the fraction of the DNA copies in a given sample that are 
methylated), methylation itself is a binary phenomenon, where for any given copy of DNA, 
specific CpGs are either methylated or unmethylated. It is therefore the methylation pattern 
of a specific cell that influences gene expression patterns of that individual cell.  Should such 
epigenetic, and thus, gene expression changes occur in individual cells harboring pre-
leukaemic genetic aberrations, they may act as the “second hit” in the causal pathway, thus 
resulting in the transition to a leukaemic cell.  
Whilst these findings support our hypothesis that altered DNA methylation may be a 
“second hit” that is causal for the development of ALL, it is pertinent to note we observed a 
significant association between folate status and methylation for only one of the four 
selected loci investigated. There are several potential explanations for this finding. It is 
plausible that the genes selected for investigation may not be folate-responsive in humans, 
or that methylation is altered at these loci only in response to more severe levels of 
depletion than were observed in this study (the majority (75%) of participants had folate 
levels within the normal range i.e. 200-600ng/ml; with 7.4% and 17.6% being below and 
above these levels respectively). Additionally, given the utilisation of SAM across a range of 
biological pathways, the relationship between folate status, SAM and DNA methylation is 
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complex and therefore not always linear.  Moreover, these relationships are highly tissue-
specific, therefore changes in gene-specific methylation observed in the murine liver in 
response to maternal folate intake may not be similar to folate responsive genes in human 
blood samples. Furthermore, whilst pyrosequencing is the gold standard measure of DNA 
methylation at specific CpG loci, this technique measures only a limited number of CpG’s 
within a small genomic region (approximately 50-80bp).  It is therefore possible, that 
methylation at other CpG sites not assayed here may be altered in response to low folate 
intake.  Finally, the small population size (n=148 mother-child dyads) may have limited our 
power to detect significant relationships between gene-specific methylation and B-vitamin 
exposure. 
To our knowledge, this is the first study to address the potential for a plausible biological 
epigenetic mechanism through which low maternal folate status may adversely influence 
the causal pathway towards childhood ALL development. Furthermore, we provide proof of 
principle that the meet in the middle approach used to test our hypothesis (Figure 1) is 
effective in its triangulation of evidence for complementary sources, using data derived 
from animal studies to inform candidate markers of exposure in human studies. Whilst 
further investigation of the role of DNA methylation in this disease pathway is warranted, 
this novel approach will allow further investigation of the role of folate (and other 
environmental factors) in ALL development.  Improved understanding of the causes and 
underlying mechanisms that promote disease development, may lead to preventative (e.g. 
public health campaigns for improved nutrition during pregnancy) and predictive (e.g. 
biomarkers for high risk individuals such as those with Downs syndrome) strategies, to 
reduce the burden of childhood ALL. 
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Table 1. Genes with altered methylation in childhood ALL and in response to maternal folate 
depletion, showing the direction of methylation change. Where both Hyper/Hypo is stated, 
differential methylation change was observed either between studies or within a given 
study. *Denotes where reported direction of methylation change was consistent BETWEEN 
studies, but both hyper and hypomethylation were reported for that gene WITHIN ONE 
study. 
Gene ID Hyper/ 
Hypomethylated 
in childhood ALL 
Hyper/ 
Hypomethylated 
in response to 
maternal folate 
depletion 
Gene ID Hyper/ 
Hypomethylated 
in childhood ALL 
Hyper/ 
Hypomethylated 
in response to 
maternal folate 
depletion 
Abca4 Hyper/Hypo Hyper Limch1 Hyper Hyper 
Adrb3 Hyper Hyper Mcoln2 Hyper/Hypo Hyper 
Aldh1l1 Hyper Hyper Meox2 Hyper Hyper 
Ank3 Hyper Hypo Mocs1 Hyper Hyper 
Ankk1 Hyper/Hypo* Hypo Mrps27 Hyper/Hypo Hypo 
Ascl2 Hyper Hyper Nde1 Hyper/Hypo Hypo 
Btbd11 Hyper/Hypo* Hyper Npy5r Hyper Hyper 
Ccdc37 Hyper Hyper P4ha3 Hyper/Hypo* Hyper 
Cdh22 Hyper Hyper Palm2-
akap2 
Hyper/Hypo Hyper 
Chst15 Hypo Hyper Pcdha1 Hyper Hyper 
Clip4 Hyper/Hypo Hyper Pcdha11 Hyper Hyper 
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Cxadr Hyper Hyper Pcdhb6 Hyper Hyper 
Dapk2 Hyper/Hypo Hyper Pdlim3 Hyper Hyper 
Dntt Hypo Hyper Phactr3 Hyper/Hypo* Hyper 
Dupd1 Hyper Hyper Prdm14 Hyper Hypo 
Dusp22 Hyper/Hypo* Hyper Rgs10 Hyper/Hypo Hyper 
Edn3 Hyper Hyper Rin2 Hyper/Hypo Hypo 
Eif2c2 Hyper/Hypo Hyper Rspo4 Hyper Hyper 
Eif5a2 Hyper Hypo Sh3gl3 Hyper Hyper 
Ern1 Hyper/Hypo Hyper Sh3rf3 Hyper/Hypo Hyper 
Gabra5 Hyper/Hypo* Hyper Slc12a7 Hyper/Hypo* Hyper 
Galnt2 Hyper/Hypo* Hyper Slc46a1 Hyper Hyper 
Gas2 Hyper Hypo Slc6a1 Hyper/Hypo* Hyper 
Gnao1 Hyper/Hypo* Hypo Sox30 Hyper Hypo 
Gpr157 Hyper/Hypo Hyper Spag17 Hyper Hyper 
Hipk1 Hyper/Hypo Hyper Srd5a2 Hyper Hypo 
Hdac11 Hyper/Hypo Hyper Stx2 Hyper/Hypo Hyper 
Jakmip1 Hyper/Hypo* Hyper Tmc5 Hyper/Hypo Hyper 
Kcna1 Hyper Hyper Tmem132c Hyper Hyper 
Kcnip1 Hyper/Hypo Hyper Traf3 Hyper/Hypo* Hyper 
Kcnk2 Hyper Hyper Trpm3 Hypo Hyper 
Kdr Hyper Hyper Usp10 Hyper/Hypo Hyper 
Kif1b Hyper/Hypo Hyper Vsx1 Hyper Hyper 
28 
 
 
